FirsthandHealth
medRxiv PreprintsInternational6 October 2026

Optimising HPV Vaccination for Cervical Cancer Prevention in Women Living with HIV: A Cost-Effectiveness Analysis Across 13 African Countries

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Background Women living with HIV (WLHIV) have an increased risk of persistent human papillomavirus (HPV) infection and cervical cancer. We evaluated the lifetime health impact and cost-effectiveness of HPV vaccination strategies targeting WLHIV across 13 African countries. Methods We developed an age-structured Markov model of HPV infection and cervical cancer in a closed cohort of 100,000 females, stratified by HIV status, and calibrated it separately for each country to age-specific cervical cancer incidence, cervical cancer mortality, and female HIV prevalence. Six HIV-targeted strategies w
— medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.